Clinical trial process
RITI® RA
From a patient’s blood sample, the RITI® RA test is able to generate an efficacy score for each biotherapy depending on the patient’s biology. The physician can also direct their prescription to the biopharmaceutical that will maximize the chances of achieving remission.
After having recently validated the CE marking, a clinical trial is underway involving 234 patients and aims to show the relevance of the RITI® RA test in the treatment of rheumatoid arthritis. The last major step before marketing the innovation is currently planned for 2025.
The clinical study in figures
Clinical trial process
Our scientific study follows a strict process and the protocol has been validated by the French National Authority for Health.
Inclusion visit (D-30 to D0)
RITI® RA Test
Final visit (D180)
Final visit: The investigator collects the information needed to calculate the DAS28 using a questionnaire, then assesses whether to continue with or stop the biotherapy that was prescribed previously. The investigator receives the results of the patient’s RITI® RA report and compares it with their patient’s condition after the biotherapy that they prescribed. The investigator gives their opinion regarding RITI® RA using a specific questionnaire.
